Celcuity (NASDAQ:CELC) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Celcuity (NASDAQ:CELC) in a report issued on Friday, Benzinga reports. They currently have a $24.00 price objective on the stock.

A number of other research analysts have also recently issued reports on CELC. HC Wainwright reiterated a buy rating and issued a $27.00 target price on shares of Celcuity in a research report on Thursday, March 28th. Craig Hallum lifted their target price on Celcuity from $20.00 to $25.00 and gave the company a buy rating in a research report on Thursday, March 28th. Finally, Stifel Nicolaus initiated coverage on Celcuity in a research report on Thursday, February 22nd. They issued a buy rating and a $40.00 target price on the stock.

Celcuity Stock Down 1.2 %

CELC stock opened at $18.09 on Friday. The company has a market cap of $550.84 million, a PE ratio of -6.72 and a beta of 0.78. The business has a 50-day simple moving average of $17.47 and a 200 day simple moving average of $14.46. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company has a quick ratio of 13.43, a current ratio of 13.43 and a debt-to-equity ratio of 0.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in shares of Celcuity by 40.3% during the fourth quarter. Bank of America Corp DE now owns 3,159 shares of the company’s stock worth $44,000 after purchasing an additional 907 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Celcuity by 7.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 27,276 shares of the company’s stock worth $256,000 after purchasing an additional 1,989 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Celcuity by 12.0% during the fourth quarter. Royal Bank of Canada now owns 18,909 shares of the company’s stock worth $276,000 after purchasing an additional 2,020 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Celcuity by 1.1% during the fourth quarter. Northern Trust Corp now owns 183,188 shares of the company’s stock worth $2,669,000 after purchasing an additional 2,035 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Celcuity by 7.6% during the second quarter. Renaissance Technologies LLC now owns 31,056 shares of the company’s stock worth $341,000 after purchasing an additional 2,200 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.